**Moscow, Russia October 10, 2017** – **InSysBio LLC**, one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for the drug development, announced a renewal of the corporate identity.
>“Lately we have become more successful and have grown bigger. We are expanding our business and are attracting new customers and partners. And now we need to become more vivid and recognizable. That is why rebranding of the company is a logical step”, Oleg Demin Jr, the head of Business Development, spoke about the reasons for such changes.
>“The official name InSysBio is now short and memorable. A new symbol is a cell made of gear-wheels. It shows that we consider the living organism and its processes as parts of the mechanism that is accurately described in our models and platforms. Corporate colors are just the employees’ favorite colors. It's so important to surround yourself with what you like and do what you love”, Oleg explained the meanings of attributes of the corporate identity.
You can meet the new InSysBio in a week at the eighth American Conference on Pharmacometrics (ACoP8), to be held from October 15th to October 18th, 2017. The meeting will take place at the Marriott Resort: Harbor Beach Hotel, Fort Lauderdale, Florida.
See InSysBio ACoP8 [Agenda here](http://insilicobio.ru/share/ACoP8_agenda.pdf). Don’t miss our exhibition **booth #4**.
| ← | December 2019 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
| ||||||
|
2
|
3
1.
03 Dec 2019 15:35
InSysBio QSP model for BTK inhibitors will be presented at the 61 ASH Annual Meeting
QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition. The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.
|
4
|
5
|
6
|
7
|
8
|
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
|
30
|
31
| |||||